Immunovia: diagnosing pancreatic cancer from one drop of blood




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Immunovia: diagnosing pancreatic cancer from one drop of blood
Released on: May 12, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Mats Grahn, CEO of Immunovia, discusses the future potential for their Antibody Microarray Technology platform for the early detection of pancreatic cancer.
  • Summary
  • Transcript
  • Participants
  • Company
Mats Grahn, CEO of Immunovia, discusses the future potential for their Antibody Microarray Technology platform for the early detection of pancreatic cancer.
Mats Grahn, CEO of Immunovia, discusses the future potential for their Antibody Microarray Technology platform for the early detection of pancreatic cancer.
Mats brings more than 25 years experiences in senior leading positions within the life science and diagnostics industry. He contributes with an extensive experience in business and strategic development, marketing, product management, product development and market access. Mats has a track record of leading international commercial operational organizations, restructuring of marketing organizations, integration of acquired companies as well as managing new start-ups. Much of his experience comes from leadership in multinational management teams and organizations in Scandinavia, Europe, USA and Asia. Previous positions include CVP Marketing Dako A/S, VP Product Management GE Healthcare, VP Marketing Amersham Biosciences, VP Laboratory Separations Pharmacia Biotech and VP Prevas Bioinformatics. Mats Grahn holds a MSc in Engineering Physics from Lund University, Sweden.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Strategy Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases earlier and more accurately than previously possible. Technology Decades of clinical immunoproteomics research resulted in the development of IMMray™, our core technology platform based on antibody microarray analysis. IMMray™ is dedicated to the early diagnosis of cancer, to predicting disease progression and to monitoring the therapeutic responsiveness of cancers. The platform technology can also be used for biomarker discovery through Immunovia’s discovery tool for proteome scanning IMMray™ PS (Proteome Survey). Immunovia’s technology is designed not only for cancer but also for autoimmune diseases. It is superior to conventional proteomic technologies that suffer from low throughput and impaired resolution and sensitivity. The first test based on Immunovia’s platform, IMMray™ PanCan-d, is now under commercialization with several clinical evidence studies in the planning phase and also ongoing. IMMray™ PanCan-d is the only blood-based test available for early detection of pancreatic cancer in stage I and stage II when the cancer is still resectable. Diagnosing patients in stage I and stage II could increase the overall 5-year survival rate from 3-4% to approx. 59%1. Immunovia’s solution combines a single-chain fragment variable (scFv) antibody library in an array-based set-up, antibody biomarker signatures and an advanced, in-house developed clinical algorithm and software for interpreting the data. The company has its own antibody library, antibody production and purification as well as its own chip/array production. Our clinical laboratory services are now undergoing validation for ISO accreditation. Mission The company’s mission is to establish its blood-based test for early diagnosis of pancreatic cancer as a standard amongst pancreatologists and diabetes physicians worldwide for detecting pancreatic cancer in high-risk groups much earlier than is possible today. Vision Ultimately, Immunovia’s vision is to significantly improve the survival rates, choice of treatment and life quality of cancer patients and their families.